Regulus Therapeutics Ownership
| RGLS Stock | USD 1.61 0.03 1.83% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 64 M | Current Value 65 M | Avarage Shares Outstanding 12.1 M | Quarterly Volatility 16.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Regulus |
Regulus Stock Ownership Analysis
About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Regulus Therapeutics recorded a loss per share of 1.02. The entity last dividend was issued on the 4th of October 2018. The firm had 1:10 split on the 29th of June 2022. Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Regulus Therapeutics contact Joseph MBA at 858 202 6300 or learn more at https://www.regulusrx.com.Besides selling stocks to institutional investors, Regulus Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Regulus Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Regulus Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Regulus Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Only 1.69% of Regulus Therapeutics are currently held by insiders. Unlike Regulus Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Regulus Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Regulus Therapeutics' insider trades
Regulus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regulus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regulus Therapeutics backward and forwards among themselves. Regulus Therapeutics' institutional investor refers to the entity that pools money to purchase Regulus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-06-30 | 947.7 K | Dafna Capital Management Llc | 2024-09-30 | 895.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 893.8 K | Ra Capital Management, Llc | 2024-09-30 | 766.8 K | Opaleye Management Inc | 2024-09-30 | 535 K | Northern Trust Corp | 2024-09-30 | 497.3 K | Cvi Holdings Llc | 2024-06-30 | 401 K | Victory Capital Management Inc. | 2024-09-30 | 398.9 K | Fmr Inc | 2024-09-30 | 328.2 K | Federated Hermes Inc | 2024-09-30 | 12.9 M | Vivo Capital, Llc | 2024-09-30 | 5 M |
Regulus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regulus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regulus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regulus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regulus Therapeutics Outstanding Bonds
Regulus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regulus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regulus bonds can be classified according to their maturity, which is the date when Regulus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| US75913MAA71 Corp BondUS75913MAA71 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.